Presternal Magnesium With Bupivacain Versus Bupivacain Only for Postoperative Pain Relief in Open Heart Surgery
Presternal Local Analgesia for Postoperative Pain Relief After Open Heart Surgery
1 other identifier
interventional
40
1 country
1
Brief Summary
Effective pain relief after cardiac surgery has assumed importance with the introduction of fast track discharge protocols that requires early weaning from mechanical ventilation. Inadequate pain control reduces the capacity to cough, mobility, increases the frequency of atelectasis, and prolongs recovery. Infiltration of local anesthetics near the surgical wound has shown to improve early postoperative pain in various surgical procedures. Magnesium is the fourth most plentiful cation in our body. It has antinociceptive effects in animal and human models of pain.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable postoperative-pain
Started Feb 2015
Longer than P75 for not_applicable postoperative-pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2017
CompletedFirst Submitted
Initial submission to the registry
July 14, 2017
CompletedFirst Posted
Study publicly available on registry
July 26, 2017
CompletedNovember 24, 2017
November 1, 2017
1.8 years
July 14, 2017
November 22, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
postoperative pain
assessing VAS scale
2 days
Secondary Outcomes (1)
hemodynamics
24 hours
Study Arms (2)
Bupivacaine magnesium
ACTIVE COMPARATOR( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
bupivacain only
ACTIVE COMPARATORbupivacaine 0.125% infusion in the presternum , for 48 hours
Interventions
bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
Eligibility Criteria
You may qualify if:
- years old
- American Society of Anesthesiologists physical status II and III
- Patients scheduled for open heart surgery with sternotomy
You may not qualify if:
- \- Emergency surgery
- Clinically significant kidney or liver disease
- Patients allergic to local anesthetic
- Patients with prolonged CPB time (\>120 min)
- Patients required intra-aortic balloon pump
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Emad Zarief Kamel Said
Asyut, 71111, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- lecturer of anesthesia and ICU
Study Record Dates
First Submitted
July 14, 2017
First Posted
July 26, 2017
Study Start
February 1, 2015
Primary Completion
December 1, 2016
Study Completion
February 1, 2017
Last Updated
November 24, 2017
Record last verified: 2017-11